Young Kwang Chae1, Andrew A Davis2, Kirtee Raparia3, Sarita Agte4, Alan Pan2, Nisha Mohindra5, Victoria Villaflor5, Francis Giles5. 1. Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL. Electronic address: young.chae@northwestern.edu. 2. Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL. 3. Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL. 4. Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL. 5. Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.
Abstract
PURPOSE: To examine clinical predictors of tumor mutational burden (TMB), to explore the association between TMB and DNA repair mutations, and to analyze TMB as a biomarker for response to immune checkpoint blockade in non-small-cell lung cancer. PATIENTS AND METHODS: TMB scores were determined retrospectively for 72 consecutive patients at our institution with next-generation sequencing comprehensive genomic profiling testing by Foundation Medicine. TMB scores were correlated with a number of clinical variables and presence of DNA repair mutations. Thirty-four patients were treated with anti-programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) therapies, and survival analyses based on TMB score were performed. In addition, tissue immunohistochemical analysis was performed for a subset of patients. RESULTS: History of smoking, but not other clinical variables, including prior treatment lines, stage of disease, and number of metastatic sites, predicted higher TMB score. Higher TMB score was significantly associated with greater number of DNA repair mutations. In the subset of patients treated with immune checkpoint blockade, higher TMB score significantly predicted overall survival, but not progression-free survival (hazard ratio = 0.10, P = .003; hazard ratio 1.1, P = .84, respectively). In a small subset of patients, PD-1/PD-L1 staining did not independently predict progression-free survival or overall survival. CONCLUSION: Tissue TMB was significantly associated with smoking history and number of DNA repair mutations. TMB is a promising biomarker for response to anti-PD-1/PD-L1 therapy, with higher TMB score predicting longer overall survival.
PURPOSE: To examine clinical predictors of tumor mutational burden (TMB), to explore the association between TMB and DNA repair mutations, and to analyze TMB as a biomarker for response to immune checkpoint blockade in non-small-cell lung cancer. PATIENTS AND METHODS: TMB scores were determined retrospectively for 72 consecutive patients at our institution with next-generation sequencing comprehensive genomic profiling testing by Foundation Medicine. TMB scores were correlated with a number of clinical variables and presence of DNA repair mutations. Thirty-four patients were treated with anti-programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) therapies, and survival analyses based on TMB score were performed. In addition, tissue immunohistochemical analysis was performed for a subset of patients. RESULTS: History of smoking, but not other clinical variables, including prior treatment lines, stage of disease, and number of metastatic sites, predicted higher TMB score. Higher TMB score was significantly associated with greater number of DNA repair mutations. In the subset of patients treated with immune checkpoint blockade, higher TMB score significantly predicted overall survival, but not progression-free survival (hazard ratio = 0.10, P = .003; hazard ratio 1.1, P = .84, respectively). In a small subset of patients, PD-1/PD-L1 staining did not independently predict progression-free survival or overall survival. CONCLUSION: Tissue TMB was significantly associated with smoking history and number of DNA repair mutations. TMB is a promising biomarker for response to anti-PD-1/PD-L1 therapy, with higher TMB score predicting longer overall survival.
Authors: Dwight H Owen; Terence M Williams; Erin M Bertino; Xiaokui Mo; Amy Webb; Catherine Schweitzer; Tom Liu; Sameek Roychowdhury; Cynthia D Timmers; Gregory A Otterson Journal: Lung Cancer Date: 2019-06-17 Impact factor: 5.705
Authors: Nike Beaubier; Martin Bontrager; Robert Huether; Catherine Igartua; Denise Lau; Robert Tell; Alexandria M Bobe; Stephen Bush; Alan L Chang; Derick C Hoskinson; Aly A Khan; Emily Kudalkar; Benjamin D Leibowitz; Ariane Lozachmeur; Jackson Michuda; Jerod Parsons; Jason F Perera; Ameen Salahudeen; Kaanan P Shah; Timothy Taxter; Wei Zhu; Kevin P White Journal: Nat Biotechnol Date: 2019-09-30 Impact factor: 68.164
Authors: Dan Sha; Zhaohui Jin; Jan Budczies; Klaus Kluck; Albrecht Stenzinger; Frank A Sinicrope Journal: Cancer Discov Date: 2020-11-02 Impact factor: 38.272
Authors: Sandip P Patel; Young Kwang Chae; Megan Othus; Francis J Giles; Donna E Hansel; Preet Paul Singh; Annette Fontaine; Manisha H Shah; Anup Kasi; Tareq Al Baghdadi; Marc Matrana; Zoran Gatalica; W Michael Korn; Jourdain Hayward; Christine McLeod; Helen X Chen; Elad Sharon; Edward Mayerson; Christopher W Ryan; Melissa Plets; Charles D Blanke; Razelle Kurzrock Journal: Clin Cancer Res Date: 2020-01-22 Impact factor: 12.531